Takeaway: ThinEras ongoing physician oversight helps ensure safe dosing, proper monitoring, and sustainable GLP-1 weight loss progress
The dispersion between Novo and Lilly again goes to show the incredible power of competition to dictate stock outcomes: despite Novos excellent financial performance since 2023 (31% growth in 2023, 25% growth in 2024, 48% EBIT margins), the stock has declined because of competition: investors think Eli Lilly is the emerging winner within GLP-1s, given the stronger weight loss profile of tirzepatide (Mounjaro/Zepbound) versus semaglutide (Ozempic/Wegovy), and Lillys more attractive weight loss pipeline assets
Starting at $199 Glutathione Nasal Spray educational content scientifically reviewed by our experts Leading authority in molecular biology, cancer research, and applied longevity science
So, these data might provide a starting point for research on using BV alone or in combination with other drugs in treating cancer and BC in particular
Both GIP from intestine K- and GLP-1- from intestine L-cells are mainly stimulated by the ingestion and absorption of carbohydrates and triglycerides or their digestion products
Does Microdosing Ozempic Work if Youre Not Overweight
